Association between anti-Ro52 antibodies and cerebral small vessel disease with neurological functional outcomes in acute ischemic stroke patients
Our findings demonstrate that anti-Ro52 antibodies are independently associated with severe CSVD burden in AIS patients. Moreover, both anti-Ro52 positivity and CSVD burden are significantly associated with worse neurological outcomes. Our study suggests that anti-Ro52 antibodies may influence stroke severity through the development and progression of CSVD.
Authors
- Guangxia Yang
- Ruoshi Wang
- Zeqin Ren
- Shengyi Zhang (ORCID: https://orcid.org/0000-0002-4542-4523)
- Kai Wang (ORCID: https://orcid.org/0000-0002-7054-704X)
- Xue Yang (ORCID: https://orcid.org/0000-0003-2653-787X)
Institutions
- Jiangnan University (CN)
- Huaian First People’s Hospital (CN)
- Wuxi Fourth People's Hospital (CN)
- Dali University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Stroke and Cerebrovascular Diseases
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.jstrokecerebrovasdis.2025.108383
- Primary Topic
- Cerebrovascular and genetic disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00